Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Granulocyte colony stimulating factor (GCSF) Clear all
Terminated Phase 2 Interventional Results available

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

NCT01518153
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

NCT00580034
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions
Campath Purged Non-myeloablative ASCT, Donor Apheresis
Drug · Procedure
Lead sponsor
David Rizzieri, MD
Other
Eligibility
17 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

NCT00003631
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, carboplatin, carmustine, cyclophosphamide, cytarabine, etoposide, ifosfamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

NCT02104427
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
TG-0054 combined with G-CSF
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Stony Brook, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas

NCT00003113
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, lomustine, procarbazine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2011 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

NCT00002982
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, carboplatin, carmustine, cytarabine, etoposide, ifosfamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

NCT01012297
View directory record Official record
Conditions
Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
201
States / cities
Phoenix, Arizona • Burbank, California • Concord, California + 138 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00265889
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

NCT00590785
View directory record Official record
Conditions
High Risk, Breast Cancer, Positive Nodes, Cyclophosphamide, Doxorubicin
Interventions
Doxorubicin, Cyclophosphamide, G-CSF, tamoxifen, ciprofloxacin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

NCT00352300
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

NCT00003035
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

NCT00653068
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Thiotepa, Vincristine Sulfate
Radiation · Procedure · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
87
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00005964
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

NCT03417284
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

NCT00005087
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

NCT01920932
View directory record Official record
Conditions
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
brentuximab vedotin, etoposide, prednisone, doxorubicin, cyclophosphamide, Dacarbazine(R), filgrastim, quality of life assessment, radiation therapy
Drug · Other · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Peoria, Illinois • Scarborough, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

NCT00025558
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, temozolomide, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 14, 2026, 5:14 PM EDT